Search

Your search keyword '"van Pesch, Vincent"' showing total 764 results

Search Constraints

Start Over You searched for: Author "van Pesch, Vincent" Remove constraint Author: "van Pesch, Vincent"
764 results on '"van Pesch, Vincent"'

Search Results

2. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

6. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

10. Longitudinal modeling of MS patient trajectories improves predictions of disability progression

16. Central Vein Sign, Cortical Lesions, and Paramagnetic Rim Lesions for the Diagnostic and Prognostic Workup of Multiple Sclerosis

18. Diagnosis and classification of optic neuritis

19. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

20. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

21. Phosphorylated tau 181 (p-tau181) as an innovative, fast and robust biomarker for cerebrospinal fluid leaks.

23. Reliability and External Validity of Digital Passive Gait Tracking in MS (P6-6.008)

24. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

26. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

30. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

31. Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination.

33. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

34. Enlarged perivascular spaces are associated with brain microangiopathy and aging in multiple sclerosis.

35. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

36. Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study

41. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

42. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

43. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

44. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

46. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

Catalog

Books, media, physical & digital resources